Liposomal bladder instillations for IC/BPS: an open-label clinical evaluation

Area of Science:

• Urology
• Pharmacology
• Biomedical Engineering

Background:

• Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic condition characterized by bladder pain and urinary urgency.
• Current treatments for IC/BPS have limitations, necessitating novel therapeutic approaches.

Purpose of the Study:

• To evaluate the safety and clinical outcomes of intravesical sphingomyelin liposomes in patients with IC/BPS.
• To explore the efficacy of 4 weekly intravesical liposome instillations.

Main Methods:

• An open-label study involving 14 IC/BPS patients treated with weekly intravesical liposomes for 4 weeks.
• Safety was assessed via laboratory tests, vital signs, and adverse event monitoring.
• Efficacy was measured using pain visual analog scales (VAS), voiding diaries, global response assessments (GRAs), and IC symptom/problem indices (ICSI/ICPI).

Main Results:

• No treatment-related adverse events were reported.
• Significant reductions in urgency VAS scores were observed at 4 and 8 weeks post-treatment (p=0.0029, p=0.0112).
• Significant improvements in pain VAS scores (p=0.0073) and combined ICSI/ICPI scores (p=0.002) were noted at 4 and 8 weeks.

Conclusions:

• Intravesical sphingomyelin liposomes were well-tolerated and safe for IC/BPS patients.
• The treatment demonstrated significant improvements in pain, urgency, and overall symptom scores.
• Further placebo-controlled trials are warranted to confirm the efficacy of this liposomal therapy for IC/BPS.